Pharmacoeconomic Analysis of Medicines Used for Bronchial Asthma in Children in Kazakhstan
Serikbayeva E. Suyunov N. Makhatov B. Atimtaikyzy A. Ibragimova A. Abdullaeva M.
1 February 2025Sciendo
Journal of Mother and Child
2025#29Issue 120 - 29 pp.
Background: This study aimed to calculate a pharmacoeconomic indicator, specifically the cost-effectiveness coefficient, for treating paediatric bronchial asthma with combined regimens of bronchodilators and inhaled corticosteroids. Material and methods: This study involves 54 children aged 6 to 12 years, who were divided into 6 groups depending on the age and severity of bronchial asthma. Treatment effectiveness is calculated by subtracting the percentage difference between exacerbation frequency and the number of patients. The calculation of pharmacoeconomic data was conducted using the cost-effectiveness ratio (CER). Results: For the treatment of mild bronchial asthma, the drug Berodual is used for inhalation through a nebuliser, moderate therapy is conducted using a combination of Flixotide and Salbutamol, and severe is stopped by a combination of Symbicort and Salbutamol. From the results obtained, notably, the CER for mild severity was 0.077 for children aged 6-8 years and 0.171 for the age group 9-12 years; for moderate severity, the CER values were 0.27 for the group 6-8 years and 0.35 for the category 9-12 years; severe asthma had the following indicators: 0.506 and 0.798 for groups aged 6-8 and 9-12, respectively. Conclusion: This studys results indicate that the most cost-effective treatment regimen is in the age groups of 6-8 years. However, the calculation of drug dosages directly depends on the patients age and the severity of the disease. Further actions in scientific works should be directed to conducting empirical, statistical studies in the field of pharmacoeconomics of bronchial asthma among children from the standpoint of the state.
accessibility of therapy for children with asthma , drug safety , economic assessment of asthma treatment , Exacerbation of asthma , pharmacotherapy
Text of the article Перейти на текст статьи
Department of Organization of Management, Economics of Pharmacy and Clinical Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty, 050000, Kazakhstan
Department of Organization of Pharmaceutical Business, Tashkent Pharmaceutical Institute, Tashkent, 100015, Uzbekistan
Center for Continuous Professional Development, Shymkent, 160011, Kazakhstan
Department of Pharmaceutical Disciplines, Astana Medical University, Astana, 010000, Kazakhstan
Department of Pharmacology, Pharmacotherapy and Clinical Pharmacology, South Kazakhstan Medical Academy, Shymkent, 160019, Kazakhstan
Department of Allergology, Republican Scientific Specialized Allergology Center, Tashkent, 100109, Uzbekistan
Department of Organization of Management
Department of Organization of Pharmaceutical Business
Center for Continuous Professional Development
Department of Pharmaceutical Disciplines
Department of Pharmacology
Department of Allergology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026